January 30, 2019
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Read More
January 30, 2019
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Read More
January 30, 2019
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Read More
January 30, 2019
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Read More
January 30, 2019
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Read More
Load More
X